Fidelity Investments’s PTC Therapeutics PTCT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$114M Sell
1,398,261
-130,101
-9% -$9.39M 0.01% 1189
2026
Q1
$104M Sell
1,528,362
-152,854
-9% -$10.8M 0.01% 1159
2025
Q4
$128M Buy
1,681,216
+69,441
+4% +$5.05M 0.01% 1064
2025
Q3
$98.9M Sell
1,611,775
-106,512
-6% -$5.55M 0.01% 1186
2025
Q2
$83.9M Sell
1,718,287
-295,275
-15% -$14M ﹤0.01% 1192
2025
Q1
$103M Buy
2,013,562
+1,193,518
+146% +$59.6M 0.01% 1085
2024
Q4
$37M Sell
820,044
-237,138
-22% -$10.1M ﹤0.01% 1503
2024
Q3
$39.2M Sell
1,057,182
-46,917
-4% -$1.57M ﹤0.01% 1472
2024
Q2
$33.8M Sell
1,104,099
-622,963
-36% -$20.2M ﹤0.01% 1466
2024
Q1
$50.2M Sell
1,727,062
-87,359
-5% -$2.45M ﹤0.01% 1330
2023
Q4
$50M Sell
1,814,421
-6,650,963
-79% -$152M ﹤0.01% 1291
2023
Q3
$190M Sell
8,465,384
-1,787,740
-17% -$66.5M 0.02% 721
2023
Q2
$417M Buy
10,253,124
+669,956
+7% +$32.8M 0.04% 467
2023
Q1
$464M Sell
9,583,168
-1,199,138
-11% -$54.8M 0.04% 435
2022
Q4
$412M Buy
10,782,306
+51,162
+0.5% +$2.13M 0.04% 460
2022
Q3
$539M Buy
10,731,144
+30,307
+0.3% +$1.48M 0.06% 331
2022
Q2
$429M Sell
10,700,837
-26,308
-0.2% -$922K 0.04% 420
2022
Q1
$400M Buy
10,727,145
+122,460
+1% +$4.72M 0.03% 514
2021
Q4
$422M Buy
10,604,685
+13,954
+0.1% +$534K 0.03% 518
2021
Q3
$394M Buy
10,590,731
+22,345
+0.2% +$918K 0.03% 520
2021
Q2
$447M Buy
10,568,386
+20,038
+0.2% +$859K 0.04% 476
2021
Q1
$499M Buy
10,548,348
+334,493
+3% +$19.9M 0.04% 434
2020
Q4
$623M Buy
10,213,855
+79,879
+0.8% +$4.71M 0.06% 336
2020
Q3
$474M Buy
10,133,976
+3,439,232
+51% +$169M 0.05% 351
2020
Q2
$340M Buy
6,694,744
+1,816,519
+37% +$89.3M 0.04% 421
2020
Q1
$218M Buy
4,878,225
+2,455,383
+101% +$124M 0.03% 480
2019
Q4
$116M Sell
2,422,842
-29,740
-1% -$1.26M 0.01% 860
2019
Q3
$82.9M Buy
2,452,582
+78,140
+3% +$3.4M 0.01% 967
2019
Q2
$107M Sell
2,374,442
-62,293
-3% -$2.46M 0.01% 883
2019
Q1
$91.7M Sell
2,436,735
-365,782
-13% -$12.3M 0.01% 946
2018
Q4
$96.2M Buy
2,802,517
+36,729
+1% +$1.32M 0.01% 862
2018
Q3
$130M Buy
2,765,788
+1,462,534
+112% +$60.5M 0.01% 831
2018
Q2
$44M Buy
1,303,254
+187,900
+17% +$5.86M 0.01% 1339
2018
Q1
$30.2M Sell
1,115,354
-42,800
-4% -$1.08M ﹤0.01% 1528
2017
Q4
$19.3M Hold
1,158,154
﹤0.01% 1738
2017
Q3
$23.2M Buy
1,158,154
+454,181
+65% +$8.89M ﹤0.01% 1645
2017
Q2
$12.9M Buy
703,973
+27,500
+4% +$371K ﹤0.01% 1850
2017
Q1
$6.66M Sell
676,473
-55,571
-8% -$673K ﹤0.01% 2100
2016
Q4
$7.99M Buy
732,044
+481,556
+192% +$5.05M ﹤0.01% 2043
2016
Q3
$3.51M Sell
250,488
-885,723
-78% -$7.2M ﹤0.01% 2260
2016
Q2
$7.98M Sell
1,136,211
-225
-0% -$1.65K ﹤0.01% 2056
2016
Q1
$7.32M Sell
1,136,436
-793,591
-41% -$13.8M ﹤0.01% 2053
2015
Q4
$62.5M Buy
1,930,027
+482,214
+33% +$14.2M 0.01% 1175
2015
Q3
$38.7M Sell
1,447,813
-1,225,750
-46% -$52.4M 0.01% 1359
2015
Q2
$129M Sell
2,673,563
-2,379,773
-47% -$139M 0.02% 918
2015
Q1
$307M Buy
5,053,336
+12,955
+0.3% +$790K 0.04% 499
2014
Q4
$261M Buy
5,040,381
+580,004
+13% +$25.5M 0.03% 557
2014
Q3
$196M Sell
4,460,377
-50,790
-1% -$1.59M 0.03% 667
2014
Q2
$118M Sell
4,511,167
-348
-0% -$7.45K 0.02% 916
2014
Q1
$118M Buy
4,511,515
+2,434,297
+117% +$65.4M 0.02% 891
2013
Q4
$35.3M Buy
2,077,218
+562,200
+37% +$9.88M 0.01% 1483
2013
Q3
$32.5M Buy
+1,515,018
New +$26.3M 0.01% 1480

Other funds holding PTCT

Fidelity Investments's PTCT Position: Q2 2026 in Review

Fidelity Investments reduced its PTC Therapeutics (PTCT) stake by 8.5% in Q2 2026, selling an estimated $9.39M and leaving 1,398,261 shares worth $114M. The position accounts for 0.01% of the portfolio, ranked #1189.

Fidelity Investments first reported a position in PTCT in Q3 2013 and has held it in 52 quarters since. The position peaked at $623M in Q4 2020. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

  • Fidelity Investments held 1,398,261 shares of PTC Therapeutics worth $114M as of Q2 2026.
  • Fidelity Investments sold 130,101 PTC Therapeutics shares in Q2 2026, an estimated $9.39M.
  • PTC Therapeutics made up 0.01% of Fidelity Investments's portfolio in Q2 2026, its #1189 holding.
  • Fidelity Investments first reported a position in PTC Therapeutics in Q3 2013 and has held it in 52 quarters since.
  • Fidelity Investments's PTC Therapeutics position peaked at $623M in Q4 2020.
  • 382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on Fidelity Investments's 13F filing for Q2 2026, filed 13 Aug 2026.